Icure Pharma Amends Capital Increase Details
아이큐어
175250
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2767
Risk-adjusted indicator based on 2767 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • SoluM Cosmetic shares (post-amendment): 18,858,802 Shares
- • Shinshin Pharmaceutical shares: 2,901,353 Shares
- • Deep Dive Partners shares: 2,417,794 Shares
- • SoluM Cosmetic post-dilution ownership: 30.55%
- • Former CEO Choi Young-kwon's pre-dilution ownership: 13.6%
AI Analysis Summary
Icure Pharmaceutical filed an amendment to its paid-in capital increase report, primarily correcting the number of shares allocated to SoluM Cosmetic from 20,502,902 to 18,858,802 shares. The capital increase involves three third-party allocators: SoluM Cosmetic (18,858,802 shares), Shinshin Pharmaceutical (2,901,353 shares), and Deep Dive Partners (2,417,794 shares). This transaction will result in SoluM Cosmetic becoming the largest shareholder with 30.55% ownership, replacing former CEO Choi Young-kwon (13.6%). The funds are intended to normalize accounts receivable/payable and resolve financial uncertainties stemming from a past embezzlement case, including an 8B KRW tax liability. The amendment itself is minor, but the underlying capital increase is significant for financial stability and governance.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.